|
CA2307278A1
(en)
*
|
2000-04-28 |
2001-10-28 |
University Of British Columbia |
Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
ES2445208T3
(es)
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
CA2531619A1
(en)
*
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
JP2007522233A
(ja)
*
|
2004-02-11 |
2007-08-09 |
アムジエン・インコーポレーテツド |
バニロイド受容体リガンド及び治療におけるそれらの使用
|
|
US7879866B2
(en)
|
2004-07-19 |
2011-02-01 |
Dorte Xenia Gram |
Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
|
|
MY145822A
(en)
*
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
US7820654B2
(en)
|
2004-09-23 |
2010-10-26 |
Dr. Reddy's Laboratories Ltd. |
Pyrimidine compounds, process for their preparation and compositions containing them
|
|
DE102005023943A1
(de)
|
2005-05-20 |
2006-11-23 |
Grünenthal GmbH |
Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
BRPI0714409A2
(pt)
*
|
2006-07-14 |
2013-03-12 |
Novartis Ag |
derivados de pirimidina como inibidores de alk-5
|
|
US20080153845A1
(en)
*
|
2006-10-27 |
2008-06-26 |
Redpoint Bio Corporation |
Trpv1 antagonists and uses thereof
|
|
WO2008076883A2
(en)
|
2006-12-15 |
2008-06-26 |
Abraxis Bioscience, Inc. |
Triazine derivatives and their therapeutical applications
|
|
CA2676715A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
|
US20100239500A1
(en)
*
|
2007-03-30 |
2010-09-23 |
Bixby John L |
Substituted triazine compounds for nerve regeneration
|
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
CN105367503A
(zh)
|
2007-10-19 |
2016-03-02 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
|
BRPI1011320A2
(pt)
*
|
2009-06-09 |
2016-06-21 |
California Capital Equity Llc |
derivados de estiril-triazina e suas aplicações terapêuticas
|
|
WO2010144394A1
(en)
|
2009-06-09 |
2010-12-16 |
Abraxis Bioscience, Llc |
Benzyl substituted triazine derivatives and their therapeutical applications
|
|
KR101457027B1
(ko)
|
2009-06-09 |
2014-10-31 |
캘리포니아 캐피탈 에쿼티, 엘엘씨 |
트리아진 유도체와 이들의 치료적 용도
|
|
ES2390326B1
(es)
*
|
2011-04-05 |
2013-08-14 |
Universidad Miguel Hernández De Elche |
Antagonistas de trpv1 y sus usos.
|
|
WO2013106614A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
CN104254533B
(zh)
|
2012-01-13 |
2017-09-08 |
百时美施贵宝公司 |
用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
|
|
EP2802576B1
(en)
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
CN104781251B
(zh)
|
2012-11-08 |
2016-12-14 |
百时美施贵宝公司 |
可作为激酶调节剂的经双环杂环取代的吡啶基化合物
|
|
KR20150079963A
(ko)
|
2012-11-08 |
2015-07-08 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
|
|
HRP20201384T1
(hr)
|
2014-01-01 |
2020-11-27 |
Medivation Technologies Llc |
Spojevi i postupci njihove upotrebe
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
TW201718571A
(zh)
|
2015-06-24 |
2017-06-01 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
|
ES2822956T3
(es)
|
2015-06-24 |
2021-05-05 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituidos con heteroarilo
|
|
WO2016210036A1
(en)
|
2015-06-24 |
2016-12-29 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
PE20191817A1
(es)
|
2017-05-11 |
2019-12-27 |
Bristol Myers Squibb Co |
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
|
|
WO2019119206A1
(en)
|
2017-12-18 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Purine inhibitors of human phosphatidylinositol 3-kinase delta
|
|
CN108863949B
(zh)
*
|
2018-07-09 |
2021-01-15 |
湖南博隽生物医药有限公司 |
一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法
|
|
CN114127075B
(zh)
|
2019-07-18 |
2024-05-14 |
百时美施贵宝公司 |
可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
|
|
EP3999508B1
(en)
|
2019-07-18 |
2023-08-30 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
WO2021026181A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
Bicyclic heterocyclic compounds useful as irak4 inhibitors
|
|
ES3059914T3
(en)
|
2019-08-13 |
2026-03-24 |
Bristol Myers Squibb Co |
Bicyclic heteroaryl compounds useful as irak4 inhibitors
|
|
CN113134005B
(zh)
*
|
2020-01-16 |
2022-09-23 |
中国药科大学 |
Trpv1通道靶向小分子的应用
|
|
EP4100408B1
(en)
|
2020-02-03 |
2024-02-28 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
WO2021158495A1
(en)
|
2020-02-03 |
2021-08-12 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
|
|
DE102022104759A1
(de)
|
2022-02-28 |
2023-08-31 |
SCi Kontor GmbH |
Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
|